Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?
Executive Summary
President-elect threatens a government bidding process to control drug pricing in his first post-election press conference.
You may also be interested in...
Trump Tries To Shame A Defiant Pfizer On Drug Pricing
President Trump called out Pfizer’s recent price increases on Twitter July 9. Pfizer was one of only four companies that took a second round of price increases in 2018, according to analysts at Morgan Stanley. CEO Read has long defended the industry's pricing practices, even as public criticism of the high drug prices has grown.
Biocon Chief Sees Bright Future For Indian Pharma In Trump Era
Biocon’s chair and managing director, Kiran Mazumdar-Shaw, tells Scrip she sees a strong partnering role for Indian firms in the Trump regime, but adds that “carte blanche” pricing that innovator companies enjoyed could come under check.
Biocon Chief Sees Bright Future For Indian Pharma In Trump Era
Biocon’s chair and managing director, Kiran Mazumdar-Shaw, tells Scrip she sees a strong partnering role for Indian firms in the Trump regime, but adds that “carte blanche” pricing that innovator companies enjoyed could come under check.